FDA
-
-
-
-
-
-
-
Humacyte plans to file for marketing approval of Symvess in Israel
-
-
-
-
-
-
-
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Humacyte reports long-term results for combat injury treatment in Ukraine
-
-
-
-
-
-
-
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
-
-
-
-
-
-
-
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
-
-
-
-
-
-
-
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
-
-
-
-
-
-
-
Trestle Bio Announces Research Collaboration with Humacyte
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

